Scientific advisors and collaborators

In order to strengthen Alligator’s research programs, the company collaborates with leading experts within relevant fields of research. Alligator currently works with the following partners and scientific advisors:

Professor Ignacio Melero

Professor Ignacio Melero, University of Navarra, Spain is an expert in immunotherapy for cancer. Professor Melero´s research focuses on translational studies of e.g. the TNF receptor superfamily and clinical development of immunotherapeutic drugs.

Professor Jeffrey Weber

Professor Jeffrey Weber, Perlmutter Cancer Center at Langone Medical Center, New York, , USA, is an expert in clinical immuno-oncology. Professor Weber has led several clinical studies of e.g. CTLA-4 and PD-1 blocking antibodies and is one of the pioneers in management of autoimmune adverse events induced by immunotherapies. With his extensive expertise in clinical development of immunotherapies, he is a key discussion partner for Alligator regarding clinical studies.

Associate Professor Sara Mangsbo

Associate Professor Sara Mangsbo, Uppsala University, Sweden, is an expert in the field of immuno-oncology. She has long-term experience in advanced model systems for tumor-directed immunotherapy of cancer, and has studied the immunotherapeutic effect of modulation of targets such as CD40, CTLA-4 and PD-1.

Professor Peter Stern

Professor Peter Stern, University of Manchester, United Kingdom, is an expert in tumor-associated antigens and virus-associated tumors. Professor Stern´s research has contributed greatly to the development of both cancer vaccines and antibody-based drugs for cancer treatment.

Professor Malin Lindstedt

Professor Malin Lindstedt, Lund University, Sweden, is an expert in dendritic cell biology and cellular assays for evaluation of novel cancer immunotherapies.

Professor Dean Felsher

Professor Dean Felsher, Stanford University, USA, is an expert in the field of oncogene-induced cancer immune evasion and the relationship between oncogenes and cancer immunotherapy.